C4 Therapeutics, Inc. reported unaudited consolidated earnings results for the second quarter ended June 30, 2021. For the quarter, the company reported revenue from collaboration agreements of $9,781,000 compared to $9,670,000 a year ago. Loss from operations was $22,116,000 compared to $10,859,000 a year ago. Net loss was $22,580,000 compared to $10,793,000 a year ago. Basic and diluted net loss per share attributable to common stockholders was $0.51 compared to $9.28 a year ago.